Amylyx Pharmaceuticals
AMLX
133 hedge funds and large institutions have $1.79B invested in Amylyx Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 8 closing their positions.
488% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 8
72% more capital invested
Capital invested by funds: $1.05B → $1.79B (+$748M)
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
40% more funds holding
Funds holding: 95 → 133 (+38)
9.64% more ownership
Funds ownership: 63.67% → 73.31% (+9.6%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
30% less call options, than puts
Call options by funds: $25M | Put options by funds: $35.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$95.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$58.9M |
| 3 |
BlackRock
New York
|
+$46.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$43.3M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$39.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$40.3M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$28.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$26.6M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$18.2M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$13.4M |
AMLX Hedge Fund Activity: Q4 2022 in Review
133 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q4 2022, worth a combined $1.79B — up 72% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new AMLX positions and 8 closed out — a net gain of 39 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $95.6M. The largest seller was Viking Global Investors, cutting an estimated $40.3M.
- 133 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q4 2022, up from 95 in Q3 2022.
- Funds reported $1.79B of Amylyx Pharmaceuticals stock for Q4 2022, up 72% quarter-over-quarter.
- 47 funds opened new Amylyx Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of +39 holders.
- The largest Amylyx Pharmaceuticals buyer in Q4 2022 was Deerfield Management, an estimated $95.6M added.
- The largest Amylyx Pharmaceuticals seller in Q4 2022 was Viking Global Investors, an estimated $40.3M sold.
Based on aggregated 13F filings for Q4 2022.